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 Background: Renal dysfunction often occurs in liver transplant (LT) recipients receiving calcineurin inhibitor (CNI)-based im-
munosuppressive regimens, increasing morbidity and mortality rates. Replacement of CNIs by mTOR inhibitor-
based immunosuppressive protocols may prevent renal impairment in LT recipients.
 Material/Methods: Outcomes in patients who underwent LT between 1996 and 2010 at our center and who were switched from 
CNI-based to mTOR inhibitor-based immunosuppression were retrospectively analyzed. Renal course, hyper-
lipidemia, and graft rejection were assessed in patients maintained on this CNI-free regimen for at least 24 
months.
 Results: Of the 85 patients switched from CNI-based to mTOR inhibitor-based, CNI-free immunosuppression, 78 met the 
inclusion criteria. Within the first 6 weeks after switching, the covariable adjusted estimated glomerular filtra-
tion rate (eGFR) increased 5.6 mL/min [95% confidence interval 2.6–8.7 mL/min, p<0.001], but there were no 
further statistically noticeable changes in eGFR. Concentrations of cholesterol and triglycerides increased sta-
tistically, noticeable within the first 12 months after drug conversion. Histologically proven graft rejection was 
observed in 4 patients (5.1%) after conversion.
 Conclusions: Conversion from CNI-based to CNI-free, mTOR inhibitor-based immunosuppression after LT is safe and can re-
sult in significant renal recovery. CNI-free, mTOR inhibitor-based immunosuppression is a potential option for 
patients with contraindications for CNIs and for LT recipients with rapid reduction in kidney function due to 
CNIs.
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Background
Technical and pharmacologic developments have resulted in 
longer-term survival after liver transplantation (LT) [1]. Most 
long-term complications after LT, including renal failure, are 
caused by the adverse effects of immunosuppressant treat-
ments [2]. Current treatment guidelines emphasize the im-
portance of individualized immunosuppression regimens that 
both avoid the adverse effects of immunosuppressive agents 
and reduce the risk of acute rejection [2]. Calcineurin inhib-
itors (CNIs) have been a cornerstone of immunosuppressive 
therapy after solid organ transplantation, significantly reduc-
ing the risk of graft rejection. CNIs, however, are associated 
with severe adverse effects, such as renal dysfunction, result-
ing in the reduction of their short- and long-term use [3,4]. 
Furthermore, mortality rates are higher in LT recipients with 
vs. without post-transplant renal dysfunction [5–7]. Therefore, 
current immunosuppressive strategies after LT are designed to 
avoid nephrotoxic drug regimens, favoring reductions in CNIs 
and CNI-free protocols [8]. Some of these protocols include 
switching from CNI-based immunosuppression to immuno-
suppressive regimens based on inhibitors of mechanistic tar-
get of rapamycin (mTOR) or combinations of mTOR inhibitors 
with reduced doses of CNIs. Although these strategies can lead 
to reduced nephrotoxicity and improved renal function [9,10], 
CNI-free immunosuppressive regimens have been associated 
with a higher risk for acute graft rejection [11,12]. This study 
was designed to evaluate the course of renal function during 
the first 24 months after conversion from a CNI (tacrolimus 
or cyclosporine) to an mTOR inhibitor (sirolimus or everolim-
us). In addition, the rates of dyslipidemia and graft rejection 
in these LT recipients were determined.
Material and Methods
This retrospective study enrolled patients who underwent LT 
between 1996 and 2010 at the University Hospital of Muenster. 
After LT, all patients were first started on an immunosuppres-
sive protocol consisting of CNI-based immunosuppression. 
Patients who were subsequently converted from a CNI-based 
immunosuppressive regimen to a CNI-free, mTOR inhibitor-
based regimen and were maintained on this regimen for at 
least 24 months were included in this study.
The study was conducted according to the ethics principles 
of the Declaration of Helsinki and was approved by the insti-
tutional review board of the University Hospital of Muenster.
Patient data, including age; sex; and creatinine, total blood cho-
lesterol, and triglyceride concentrations, were collected at the 
time of drug conversion and at defined time points during follow-
up. All changes in immunosuppressive drugs were documented. 
Data on the clinical course of patients were collected from pa-
tient files for at least 24 months after drug conversion.
All included patients received mTOR inhibitor-based immuno-
suppression for at least 24 months after conversion. Patients 
who also received CNI were not included. We also excluded 
patients who switched from mTOR inhibitor-based immuno-
suppression to another immunosuppressive regimen or who 
discontinued mTOR inhibitors; those who experienced loss of 
graft function; and patients who died or were lost to follow-up.
Renal function was evaluated by determining the estimated 
glomerular filtration rate (eGFR) using the MDRD4 formula [13].
Immunosuppressive regimen
The standard post-LT immunosuppressive regimen at our center 
included tacrolimus or cyclosporine with/without mycopheno-
late mofetil and with/without prednisolone. The CNI-free reg-
imen included everolimus or rapamycin with/without myco-
phenolate mofetil and with/without prednisolone.
Statistical analysis
Statistical analyses were performed using SAS software, ver-
sion 9.4, for Windows (SAS Institute, Cary, NC, USA). Inferential 
statistics were intended to be exploratory rather than confir-
matory. P-values were used to generate new hypotheses and 
represent only a metric measure of evidence against the re-
spective null hypothesis. Thus, neither a global significance 
level nor local levels were determined, and there were no ad-
justments for multiplicity. P-values ≤0.05 were considered sta-
tistically significant.
The primary target parameter was eGFR (mL/min). Secondary 
parameters included cholesterol (mmol/L) and triglyceride 
(mmol/L) concentrations. Standard univariate statistical anal-
yses were performed to describe demographic and clinical pa-
rameters. Categorical variables are reported as absolute and 
relative frequencies. Normally distributed continuous variables 
are reported as mean±standard deviation, and non-normally dis-
tributed continuous variables as median (minimum, maximum).
Longitudinal analyses were performed using multivariable lin-
ear mixed models (LMM) to quantify differences between the 2 
immunosuppressive regimens. Target variables were eGFR and 
cholesterol and triglyceride concentrations. Due to the skewed 
distribution of triglyceride concentrations, they were log-trans-
formed. Details of the model are described in the legends to 
Tables 1 and 2. Pairwise comparisons between the regimens 
at each time point were estimated within the multivariable 
LMM. Results are reported as regression coefficients and cor-
responding 95% confidence intervals (95% CI).
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Results
During the period from 1996 to 2010, 85 patients were switched 
from CNI-based immunosuppression to mTOR-based, CNI-free 
immunosuppression. Of these, 4 (4.7%) discontinued treatment 
because of adverse events (2 each due to proteinuria and pan-
cytopenia), and 3 (3.5%) were lost to follow-up. The remaining 
78 patients (24 females, 54 males; mean age at transplanta-
tion, 53.1±12.9 years) met the inclusion criteria for this study 
and were included in the statistical analysis. Median time from 
LT to drug conversion was 12 months (range, 1–180 months). 
Table 3 shows the demographic and clinical characteristics of 
the study population. Of the 78 included patients, 39 (50%) 
were switched from tacrolimus to sirolimus, 32 (41%) from ta-
crolimus to everolimus, 3 (4%) from cyclosporine to sirolimus, 
and 4 (5%) from cyclosporine to everolimus.
Because there were no differences among the immunosuppres-
sive regimens in the time courses of all target parameters, an 
interaction effect between the regimens and time points was 
not included in the LMMs.
Course of renal function
Baseline eGFR at the time of drug conversion was 55.2±25.3 
mL/min. Six weeks after drug conversion, eGFR showed a co-
variable adjusted increase of 5.6 mL/min [95% CI 2.6–8.7 mL/
min, p<0.001]. Table 1 shows the course of eGFR as calculat-
ed by the multivariate LMM. Changes from baseline in eGFR at 
all time points were statistically significant, but changes from 
week 6 were not. Furthermore, multivariate analysis showed 
that only female sex (p=0.038) and increased age (p<0.001) neg-
atively influenced eGFR. Increased eGFR after conversion was 
independent of immunosuppressive regimens before and after 
 Independent variable
Model-based estimates of eGFR (ml/min)
 
P-value Estimate 
Lower 95% 
confidence limit
Upper 95% 
confidence limit
Intercept –2972.7 –7228.2 1282.8 0.1679
Sex (m vs. f) 10.9 0.6 21.2 0.0380
Time points 0.0094
6 weeks vs. baseline 5.6 2.6 8.7 0.0003
3 months vs. baseline 5.5 2.6 8.3 0.0002
6 months vs. baseline 4.4 0.9 7.8 0.0142
12 months vs. baseline 5.2 1.8 8.7 0.0033
18 months vs. baseline 4.6 1.3 7.9 0.0061
24 months vs. baseline 4.3 0.7 7.8 0.0182
Year of LT (per year: 1996 to 2010) 1.52 –0.6 3.6 0.1515
Age in years –0.6 –1.0 –0.3 <0.0001
Time from LT to drug conversion (months) 0.02 –0.2 0.2 0.8385
Diabetes (yes vs. no) –3.3 –11.8 5.3 0.4510
Hypertension (yes vs. no) –7.0 16.4 2.4 0.1450
HCV (yes vs. no) 8.9 –12.6 30.3 0.4176
Drug after conversion (sirolimus vs. everolimus) 5.5 –2.9 13.9 0.1991
Drug before conversion (cyclosporine vs. tacrolimus) 3.5 –18.7 25.7 0.7576
Table 1. Factors associated with renal function (eGFR, ml/min), as determined by a linear mixed model.
Regression coefficient estimates and 95% confidence limits of fixed effects on eGFR (ml/min). Covariates were: year of LTx (year: range 
1996 to 2010), gender, age at LTx, time since LTx to drug conversion, CNI inhibitor before conversion, diabetes, hypertension, HCV. 
A random intercept for each patient and an unstructured covariance structure (UN) for the residuals were included. The variances 
were estimated using the empirical sandwich estimator. P-values are from the related F-tests or t-tests. eGFR – estimated glomerular 
filtration rate; HCV – hepatitis C virus.
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conversion; time between LT and conversion; year of LT; and 
presence of diabetes, hypertension, and HCV infection. Table 4 
shows descriptive statistics of eGFR during the observation time.
Lipid changes after drug conversion
During the first 12 months after conversion, mean blood cho-
lesterol concentrations increased from 187.1±46.9 mmol/L to 
216.7±57.7 mmol/L. Adjusted blood cholesterol concentration 
increased by 29.6 mmol/L [95% CI 18.6–40.7 mmol/L, p<0.001]. 
No further increases were observed after 12 months. Table 2 
shows changes in cholesterol relative to different variables. 
Except for time from conversion, no other variable had a sta-
tistically significant effect on cholesterol concentration.
Mean serum triglyceride levels increased from 168.9±84.6 
mmol/L at baseline to 210.3±135 mmol/L at 12 months, but 
decreased to 179.0 mmol/L at 24 months. Triglyceride con-
centration increased significantly over the first 12 months 
(p=0.0034), but the change from baseline to 24 months was 
not significant (p=0.3668).
Of the 78 patients, 25 (32%) required treatment with statins 
due to hyperlipidemia that developed after conversion to 
mTOR-inhibiting agents.
Rejection
During the 24 months after conversion to the mTOR inhibitor-
based immunosuppression, 4 patients (5.1%) experienced his-
tologically acute graft rejection.
In the multivariate adjusted model, eGFR and lipid concentra-
tions did not differ noticeably in patients switched to evero-
limus and sirolimus. Because of the small number of patients 
who experienced graft rejection, the difference in rejection 
rate between patients switched to everolimus and sirolimus 
could not be determined.
 Independent variable
Model-based estimates of Cholesterol (mmol/L)
 P-value 
Estimate 
Lower 95% 
confidence limit
Upper 95% 
confidence limit
Intercept 3231.4 –5394.9 11858 0.4573
Sex (m vs. f) –22.9 –48.8 3.0 0.0828
Point of time <0.0001
 12 months vs. baseline 29.6 18.6 40.7 <0.0001
 18 months vs. baseline 27.6 16.5 38.6 <0.0001
 24 months vs. baseline 17.3 5.3 29.3 0.0049
Year of LTx (per year: 1996 to 2010) –1.5 –5.8 2.7 0.4835
Age in years 0.02 –0.8 0.9 0.9707
Time from LT to drug conversion (months) 0.2 –0.6 0.1 0.1817
Diabetes (yes vs. no) 4.1 –19.0 27.3 0.7271
Hypertension (yes vs. no) 1.3 –17.6 20.2 0.8960
HCV (yes vs. no) –13.2 –42.2 15.7 0.3682
Drug after conversion (sirolimus vs. everolimus) 9.6 –9.0 28.2 0.3095
Drug before conversion (cyclosporine vs. tacrolimus) 18.8 –21.0 58.9 0.3520
Table 2. Factors associated with total cholesterol concentrations, as determined by a linear mixed model.
Regression coefficient estimates and 95% confidence limits of fixed effects on cholesterol (mmol/L). Covariates were: year of LTx (year: 
range 1996 to 2010), gender, age at LTx, time since LTx to drug conversion, CNI inhibitor before conversion, diabetes, hypertension, 
HCV. A random intercept for each patient and an unstructured covariance structure (UN) for the residuals were included. The variances 
were estimated using the empirical sandwich estimator. P-values are from the related F-tests or t-tests. Abbreviations: HCV, hepatitis C 
virus.
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Discussion
Clinical studies have shown that both reduction of CNI dose 
and CNI discontinuation were associated with significant re-
nal recovery [15,16]. The findings shown here are consistent 
with these earlier results, in that elimination of CNIs by con-
version to mTOR inhibitor-based immunosuppression result-
ed in a significant improvement in renal function, as shown 
by the increase in eGFR. Interestingly, this improvement oc-
curred within 6 weeks after drug conversion, with no further 
improvement observed thereafter.
Renal recovery after conversion was independent of the time 
period between LT and conversion, indicating that renal re-
covery can occur after CNI elimination despite existing CNI-
related parenchymal renal damage [17,18]. A multivariate ad-
justed model found that the only factors having a noticeable 
negative influence on renal function (e.g., lower eGFR) were 
increased age and female sex, consistent with studies show-
ing that female sex and increased age were associated with 
increased renal vulnerability to noxious agents and to drug 
toxicity [19–21].
Age at LT (years) 53.1±12.9/55 (12, 71)
Age at drug conversion (years) 55.8±12.5/57 (19, 76)
Sex (females/males) 24 (30.8%)/54 (69.2%)
Time from LT to drug conversation (months) 31.0±40.6/12 (1, 180)
Patients with HCV  7 (9.0%)
Arterial Hypertension  48 (61.5%)
Diabetes  31 (39.7%)
IS medication before conversion
 Tacrolimus  71 (91.0%)
 Cyclosporine  7 (9.0%)
IS medication after conversion
 Sirolimus  42 (53.8%)
 Everolimus  36 (46.2%)
Indications for LT
 Hepatocellular carcinoma  22 (28.2%)
 Alcohol-induced cirrhosis  15 (19.2%)
 Hepatitis B/C  11 (14.1%)
 Primary sclerosing cholangitis  7 (9.0%)
 Cryptogenic liver cirrhosis  5 (6.4%)
 Polycystic liver disease  5 (6.4%)
 Autoimmune hepatitis  4 (5.1%)
 Biliary atresia  2 (2.6%)
 AAT deficiency  2 (2.6%)
 Primary biliary cirrhosis  1 (1.3%)
 Idiopathic acute liver failure  1 (1.3%)
 Familial amyloid polyneuropathy  1 (1.3%)
 Wilson’s disease  1 (1.3%)
 Secondary sclerosing cholangitis  1 (1.3%)
Table 3. Demographic and clinical characteristics of the LT recipients included in this study.
Results are reported as mean ± standard deviation; median (minimum, maximum); or absolute and relative frequencies. AAT – alpha 1 
antitrypsin; HCV – hepatitis C virus; LT – liver transplantation; IS – immunosuppression.
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Conversion to mTOR-inhibitor-based immunosuppression was 
also associated with the development of mixed hyperlipidemia. 
Total cholesterol and triglyceride concentrations increased sig-
nificantly during the first 12 months after conversion. In all of 
these patients, hyperlipidemia was managed by dietary mea-
sures or by administration of lipid-lowering agents.
Although the rejection rate was found to be significantly 
greater in LT recipients after CNI withdrawal [12], our study 
found that the rejection rate after switching to mTOR-inhib-
iting agents was 5.1%, similar to that in patients maintained 
on CNIs [11,12]. This discrepancy may have been due to the 
timing of drug conversion, in that our patients were convert-
ed a mean of 31 months after LT, whereas in the earlier study 
CNIs were withdrawn a mean of 30 days after LT [12]. All re-
jections in our study were successfully managed using pulse 
steroid therapy and adjustment of blood trough levels of im-
munosuppressive agents.
To the best of our knowledge, no previous study has compared 
the efficacy and safety of everolimus and sirolimus after LT. Our 
study found that these 2 drugs were not different in inducing 
renal improvement and in their incidence of hyperlipidemia.
In conclusion, conversion from CNIs to mTOR-inhibiting agents 
can result in improved renal function in LT recipients. Moreover, 
renal recovery can be achieved even when patients are switched 
many years after LT. These results also show that mTOR inhibi-
tors are safe in LT recipients and are associated with a reason-
able allograft rejection rate in stable LT recipients. Most of the 
adverse effects could be managed without drug withdrawal.
Conclusions
In 2013, the US FDA approved everolimus as the first mTOR-
inhibiting agent for the prophylaxis of allograft rejection after 
LT. Due to the higher rejection rate after withdrawal [12], the 
FDA approved everolimus in combination with reduced tacro-
limus. Our findings, however, indicate that withdrawal from 
CNIs and treatment with mTOR-inhibitor-based immunosup-
pression may be an option in LT patients with serious CNI-
associated adverse effects and rapid loss of renal function.
Conflict of interest
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Time 
point 
GFR (mL/min)
N Mean
Standard 
Deviation
Minimum Q25 Median Q75 Maximum
Conversion 78 55.2 25.3 11.0 35.0 50.0 75.0 137.3
6 weeks 78 60.9 25.5 11.9 40.8 57.0 78.1 128.3
3 months 78 60.7 24.8 8.0 43.0 56.0 77.9 134.8
6 months 78 59.6 23.1 16.0 43.0 55.0 76.4 116.5
12 months 78 60.5 25.3 16.0 42.0 55.5 76.1 150.7
18 months 78 59.8 25.0 16.0 43.0 53.7 70.2 150.7
24 months 78 59.5 24.7 15.8 43.0 55.0 75.3 136.2
Table 4. Decriptive statistics of GFR over time.
Q25 – 25% quantile; Q75 – 75% quantile.
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